Trending NewsTrending NewsLowest-Rated StocksLowest-RatedNASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $447.49 -8.19 (-1.80%) Closing price 04:00 PM EasternExtended Trading$447.00 -0.49 (-0.11%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Medpace Stock (NASDAQ:MEDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medpace alerts:Sign Up Key Stats Today's Range$427.27▼$449.7850-Day Range$293.03▼$477.7352-Week Range$250.05▼$501.30Volume763,602 shsAverage Volume683,834 shsMarket Capitalization$12.57 billionP/E Ratio33.27Dividend YieldN/APrice Target$411.10Consensus RatingHold Company Overview Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH. Read More Medpace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreMEDP MarketRank™: Medpace scored higher than 74% of companies evaluated by MarketBeat, and ranked 282nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageMedpace has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.15% Earnings GrowthEarnings for Medpace are expected to grow by 11.15% in the coming year, from $12.29 to $13.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 33.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 33.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.11.Price to Earnings Growth RatioMedpace has a PEG Ratio of 7.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 72.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.02% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Medpace has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.62 Percentage of Shares Shorted14.02% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Medpace has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.76 News SentimentMedpace has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for Medpace this week, compared to 12 articles on an average week.Search Interest12 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Stock News HeadlinesEngaging In Options Activity, Cornelius P. McCarthy III Exercises Options Valued At $740K In Medpace Hldgs1 hour ago | benzinga.comMedpace Hldgs's Options: A Look at What the Big Money is Thinking1 hour ago | benzinga.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 25 at 2:00 AM | Porter & Company (Ad)Medpace Holdings, Inc. (MEDP) Stock Forecasts1 hour ago | finance.yahoo.comMedpace (MEDP) Stock Trades Down, Here Is Why1 hour ago | msn.comMedpace Holdings, Inc. (MEDP): A Bull Case Theory1 hour ago | insidermonkey.comMedpace (NASDAQ:MEDP) Shares Gap Up Following Earnings BeatJuly 24 at 2:42 AM | americanbankingnews.comMedpace Beats Q2 Revenue EstimatesJuly 22 at 10:01 PM | fool.comSee More Headlines MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $332.23 at the start of the year. Since then, MEDP shares have increased by 34.7% and is now trading at $447.49. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) posted its earnings results on Monday, July, 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm's revenue was up 14.2% compared to the same quarter last year. Read the conference call transcript. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's top institutional investors include Riverbridge Partners LLC (1.51%), Annex Advisory Services LLC (0.33%), Argent Capital Management LLC (0.28%) and Swedbank AB (0.25%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Fred B Davenport Jr, Ashley M Keating and Robert O Kraft. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings7/21/2025Today7/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Price Target for Medpace$411.10 High Price Target$510.00 Low Price Target$330.00 Potential Upside/Downside-8.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$13.45 Trailing P/E Ratio33.27 Forward P/E Ratio36.41 P/E Growth7.96Net Income$404.39 million Net Margins18.74% Pretax Margin22.20% Return on Equity67.66% Return on Assets21.86% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.73 Sales & Book Value Annual Sales$2.23 billion Price / Sales5.76 Cash Flow$14.27 per share Price / Cash Flow31.35 Book Value$6.14 per share Price / Book72.88Miscellaneous Outstanding Shares28,742,000Free Float22,907,000Market Cap$12.86 billion OptionableOptionable Beta1.47 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:MEDP) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.